A carregar...
Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells
Breast cancer can be classified into molecular subtypes. Tumors overexpressing HER2 protein are more aggressive and metastatic; hence, patients have a poor prognosis. Anti-HER2 strategies, such as the monoclonal antibody Trastuzumab (Tz), have therefore been developed. Despite this progress, not all...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5995169/ https://ncbi.nlm.nih.gov/pubmed/29899874 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25480 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|